Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence

Inclusion Criteria:

- Be one of the first 225 subjects who were randomly assigned to treatment in G201002
(Phase 2 study) and have completed the 12-week treatment and 16-week durability
periods

- Be able to read, understand, and provide written, dated informed consent prior to
enrollment in the current study (within 2 weeks of completing G201002) and be likely
to comply with the study protocol and communicate with study personnel about AEs and
other clinically important information

- Agree to maintain a stable dose of any medication known to affect lower urinary tract
function, including but not limited to anticholinergics, tricyclic antidepressants,
beta-3 adrenergic agonists, or α-adrenergic blockers, throughout the duration of the
study

Exclusion Criteria:

- Starts any new treatment (medication, pelvic floor physical therapy, or other
treatment known to impact the pelvic floor) after completing G201002 that is known or
suspected to affect lower urinary tract function, including vaginal rejuvenation

- Has a current or past history of any physical condition that, in the investigator's
opinion, might put the subject at risk or interfere with interpretation of study
results